ArticleIET systems biology
Comprehensive Analysis of FOXO1 as a Tumour Suppressor Biomarker Related to Immune Infiltration and Cell Proliferation of Hepatocellular Carcinoma.
Article in IET systems biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a cancer with high morbidity and mortality, and effective biomarkers for indicating prognosis and treatment have still not been fully investigated. Forkhead box O1 (FOXO1), as a crucial transcription factor, its role remains to be elucidated in HCC. Herein, by combining bioinformatics techniques and basic experiments, the expression and function of FOXO1 in HCC were preliminarily explored. The expression profile, prognostic analysis, mutation landscape, immune infiltration abundance and tumour stemness index of FOXO1 were determined in TCGA and GEO databases. Moreover, a FOXO1-related nomogram was constructed and validated in the HCC cohort. Ultimately, the expression and function of FOXO1 in HCC were verified through basic experiments, such as western blotting, RT-qPCR, immunohistochemical analysis, CCK8 assay and clone formation assay. The expression of FOXO1 was decreased and was associated with a favourable prognosis in majority of cancers. Mutation landscapes of FOXO1 in various cancers were described and revealed the significant association between FOXO1 expression and TMB/MSI. A FOXO1-based Nomogram was constructed and verified in HCC cohort. The expression and function of FOXO1 were closely related to the HCC immune microenvironment. Moreover, there was a negative correlation between the FOXO1 expression and tumour stemness index. Finally, the expression pattern of FOXO1 in HCC and its association with tumour proliferation ability were verified through basic experiments. FOXO1 was identified to regulate the immune microenvironment and the tumour proliferation ability in HCC, demonstrating its potential as a therapeutic target for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.